Cell Microsystems

Cell Microsystems

Cell Microsystems operates from Durham, North Carolina, providing a suite of benchtop instruments for single-cell isolation, imaging, and culture. Its product line reflects an engineering-led approach to cell biology workflows: the CellRaft AIR System enables automated colony picking from a shared-media array, while the BioFlux line introduces controlled shear flow for assays that mimic vascular or mucosal environments. The CERO 3D Incubator & Bioreactor supports organoid and spheroid culture with integrated pH, CO2, and temperature regulation. The firm's instrument catalog addresses multiple stages of cell-based research. The CASY Cell Counter & Analyzer handles label-free viability assessment across a wide particle-size range — from yeast and bacteria to stem-cell aggregates — without dyes or reagents. The TIGR Tissue Grinder and Dissociator uses a semi-automated, enzyme-free mechanical protocol to produce single-cell suspensions for downstream genomic or proteomic analysis. For electrophysiology, the IonFlux Mercury family delivers parallel patch-clamp recordings across 16 to 256 channels, with continuous fluid exchange and temperature control up to 40°C. Public information on the firm's financial scale, ownership, and team is limited. No third-party publication has reported an AUM figure, fundraising activity, or headcount. The corporate website focuses on product specifications and application notes — CRISPR gene editing, cancer research, stem cell biology, immunology, and neurobiology — without listing executive leadership, board composition, or investor relationships. An Altss research record identifies the headquarters as Durham, United States, with the domain cellmicrosystems.com, but no founding year, principals, or geographic footprint beyond the single office are publicly confirmed. Structurally, Cell Microsystems functions as a scientific-instruments company rather than a traditional family office or fund manager. Its value proposition rests on hardware-and-consumable sales to academic labs and biopharma R&D groups. The absence of disclosed venture backing, grant portfolios, or manufacturing-partner disclosures means the firm's capital structure and ownership remain opaque. For allocators, the relevant question is whether Cell Microsystems ever raises institutional equity or operates solely as a self-funded product shop — a detail the current public record does not answer.